Skip to content

$62M for Remedy Robotics, Capstan’s robot nails first U.S. mitral valve replacement

·StartupReader editorial desk· 4 min readReviewed by our editors
FUNDING. $62M raised by Remedy Robotics, AI-powered robotic platform. led by DCVC, UC Investments, Skip Capital, Hostplus. Stage: Series B.

Remedy Robotics has raised $62 million in Series B funding to advance its AI-powered robotic platform for neurovascular procedures, while Capstan Medical marked a clinical milestone with the first U. S. transcatheter mitral valve replacement using its investigational robot. The moves highlight how medtech robotics are advancing beyond established markets like laparoscopic surgery into the high-stakes, high-risk world of cardiovascular intervention—where precision and access remain critical unmet needs.

The funding for Remedy, led by DCVC with new backers including UC Investments, Skip Capital, and Australian pension fund Hostplus, will accelerate a pivotal trial with the University of California. The company’s N1 system, which can operate on-site, remotely, or with some level of automation, uses AI to process preoperative scans, model procedures ahead of time, and assist with real-time guidance during endovascular interventions. Remedy claims its platform—already deployed in over 100 hospitals globally—can improve outcomes for patients in regions where specialized care is scarce. The funding follows Remedy’s October 2025 announcement that it had completed remote neurointerventional procedures with the N1 system, reinforcing its goal of making complex vascular treatments more accessible.

This investment reflects a shift in medtech robotics beyond traditional surgical assistants. Remedy’s focus on neurovascular interventions—a field where manual techniques still dominate—positions it to disrupt a niche where human error and geographic barriers often limit treatment quality. However, the company’s push toward more autonomous operations could face scrutiny from regulators and clinicians accustomed to direct physician oversight. Still, the involvement of UC Investments suggests confidence in Remedy’s academic partnerships as a pathway to credibility.

Meanwhile, Capstan Medical’s Compass robotic system achieved a significant breakthrough: the U. S.’ s first transcatheter mitral valve replacement (TMVR) using its investigational robot. The patient was discharged in stable condition, marking progress for Capstan, which had previously conducted first-in-human robot-assisted TMVR procedures in Chile earlier this year. Mitral valve replacement is far more technically demanding than aortic valve procedures due to the valve’s complex anatomy, and robotic assistance has been slower to develop in this area. Capstan’s system combines a flexible, multi-axis catheter with robotic navigation, aiming to improve catheter stability and precise implant positioning through a handheld controller.

Capstan’s achievement is notable for two key reasons. First, it demonstrates that robotics can now tackle procedures where conventional surgery is too risky for high-risk patients. The hospital’s structural heart program director noted that this technology could expand treatment options for those who cannot undergo traditional open-heart surgery. Second, the procedure follows Capstan’s $110 million raise in 2024, which included support from a major player in surgical robotics—a signal that the company may benefit from established industry expertise as it moves forward.

The contrast between Remedy and Capstan reflects different approaches in medtech robotics. Remedy is focused on using AI to broaden access to specialized care, while Capstan is refining robotic precision for procedures where human dexterity alone has proven insufficient. Both face familiar challenges: proving their methods are better than existing ones, navigating regulatory hurdles, and convincing clinicians to adopt new workflows. Yet their progress suggests that robotics in cardiovascular care are moving beyond incremental improvements toward transformative potential.

What to watch next: Remedy’s pivotal trial timeline: The company’s study with UC will be a key test. Delays or positive interim results could shift investor confidence. Capstan’s regulatory path: TMVR remains a high-stakes area. Whether Capstan can replicate its U. S. success in larger trials will determine its competitive position against established players like Abbott, Edwards, and Medtronic. Industry partnerships: With backing from a leading surgical robotics firm, Capstan may accelerate its development—but potential overlaps with future products from that company could create challenges.

The two startups also highlight a broader trend: the growing integration of robotics and AI in medtech. Remedy’s AI capabilities and Capstan’s precision engineering suggest that the next generation of medical robotics will depend on advancements in both hardware and software. For founders and investors, the focus isn’t just on whether robotics can replace human hands, but on how quickly they can surpass them.

Sources: medtechdive.com

“Two medtech startups are pushing robotics into the most complex corners of cardiovascular surgery—but their paths reveal how funding and clinical milestones are reshaping the race for precision.”
— StartupReader
ShareLinkedInXWhatsApp

One of the funding rounds reported in the week of 16–22 November 2026. See every round that week.

Read the original reporting

The outlets below did the original reporting.

Related briefs

This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.